Influenza Vaccine Market Insights and Trends 2022-2026
Influenza Vaccine typically known as flu
shot and is used for protection against influenza virus. An influenza vaccine
is a combination of three viruses types namely, influenza type A with H3N2
virus strain, influenza type A with H1N1 virus strain and influenza type B virus
strain. Influenza is a contagious respiratory illness caused by influenza
viruses, which may cause mild to severe illness.
Severity of the illness might land up to hospitalization or
death. The risk of the serious flu complication is more in the age group such
as older people, young children, and people with certain health
conditions. It should be a habit to get vaccinated every year against this
virus, as part of the best practice to avoid getting infected.
The categorization of this influenza virus is done into the
mentioned categories, influenza A (H1N1) virus, an influenza A (H3N2) virus,
and one or two influenza B viruses, depending on the flu vaccine. Patients show
symptoms like chills, cough, sore throat, running nose, body aches, headache,
fatigue, some cases people may have vomiting and diarrhea, this is commonly
seen in children than adults. This flu is mostly spread through droplets from
infected people, flu cough, sneeze or talks. A person’s eyes, mouth and nose
are the entry channels through which the virus enters.
Infection can be spread by most healthy adults beginning 1 day
before symptoms develop and up to 5 to 7 days after becoming sick. Once a
person is symptomatic to the virus until onset, the span is 1 to 4 days, with
an average of 2 days. For children and people with weak immune system; they
might infect others even for a longer period of time.
The complication of virus may include bacterial pneumonia, ear
infections, sinus infections, dehydration, and worsening of chronic medical
conditions, such as congestive heart failure, asthma, or diabetes. Chronic
medical condition may occur such as congestive heart failure, asthma, or
diabetes.
Influenza
Vaccine Market: Drivers and Restraints
The key drivers for seasonal influenza vaccines therapeutic
market is increasing disease awareness on influenza caused by threat of
pandemic influenza, wider vaccination coverage and rising government support
for immunization against seasonal influenza. Also, the major market players
have a great pipeline products, thus making a strong product portfolio.
The major restrains of this market are variable demand, limited
production capacity, a high level of required investment, and strict
regulations present barriers to new entrants.
Influenza
Vaccine Market: Regional Overview
The geographical market of seasonal influenza vaccines is spread
across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong,
Malaysia, India and Singapore. The seasonal influenza vaccine market across the
seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and
Japan, was projected to rise from $3.1 billion in 2015 to $4.3 billion by 2025,
at a compound annual growth rate of 3.3%.
Philippines' seasonal influenza vaccine market is the most
attractive for Asia-Pacific region both in terms of value and growth rate;
other attractive markets in terms of growth rate are Malaysia and Singapore.
Australia's seasonal influenza vaccine market is one amongst the large sized
attractive market forecast to grow at a healthy growth rate during the period
2011–2018.
Influenza
Vaccine Market: Key Players
The key players in this market include GlaxoSmithKline,
Novartis, CSL, MedImmune, Sanofi-Pasteur, Solvay, Sinovac Biotech and Hualun
Biologicals. Some of the other market players are ID Biomedical Corp. of Quebec
(distributed by GlaxoSmithKline), Seqirus, Protein Sciences, MedImmune, etc.
Influenza
Vaccine Market: Segmentation
The major segmentation of the vaccine market can be
done under three major headers mentioned as end users, treatment type and
geographical segmentation.
Based on the end
users, it can further sub-segmented as following:
- Paediatrics
- Adolescence
- Adults
- Elderly
These end users influence the market through
different channels of administration of the vaccines. The channels like
clinics, hospitals, mail service, prisons, universities, retail service,
combined retail, etc.
Treatment of seasonal influenza is dominated by two
categories of treatment options, vaccines and antiviral therapies. The
categorization of this influenza virus is done into the mentioned categories,
influenza A (H3N2) virus, an influenza A (H3N2) virus, and one or two influenza
B viruses, depending on the flu vaccine.
The third major segmentation category is the
geographical segmentation. This would depend upon the geographical market which
is most flouring for the given vaccine market.
Click
to View Full Report@ https://www.futuremarketinsights.com/reports/seasonal-influenza-vaccines-therapeutics-market
Comments
Post a Comment